文献速递药物相互作用治疗药物监测与药物基因组学

GCDCA-3G与GDCA-3G可检测GDC-0810对OATP1B的弱抑制

Glycochenodeoxycholate and glycodeoxycholate 3-O-glucuronides, but not hexadecanedioate and tetradecanedioate, detected weak inhibition of OATP1B caused by GDC-0810 in humans.
PubMed 文献 · Br J Clin Pharmacol · 2023-02-14

本研究在GDC-0810存在与否时测定血浆中脂肪酸、胆汁酸及其结合物的浓度,评估其作为OATP1B内源性生物标志物的潜力。结果显示十六烷二酸和十四烷二酸浓度未升高,而GCDCA-3G和GDCA-3G的Cmax几何均值比分别为1.58(95%CI 1.13-2.22)和1.49(95%CI 1.21-1.83),提示二者可捕获OATP1B的弱抑制。

要点

  • GCDCA-3G和GDCA-3G的Cmax在GDC-0810存在时升高,可检测OATP1B弱抑制。
  • 十六烷二酸和十四烷二酸浓度未因GDC-0810而升高。
  • GCDCA-3G与GDCA-3G可作为补充粪卟啉I/III的OATP1B生物标志物。

核心结论

  • GCDCA-3G和GDCA-3G是有望捕获OATP1B弱抑制的内源性生物标志物,十六烷二酸和十四烷二酸未显示此作用。

研究设计与样本

  • 在GDC-0810存在与不存在时测定血浆中脂肪酸、胆汁酸及其硫酸或葡萄糖醛酸结合物的浓度。

主要发现

  • GCDCA-3G的Cmax几何均值比(95%CI)为1.58(1.13-2.22)。
  • GDCA-3G的Cmax几何均值比(95%CI)为1.49(1.21-1.83)。
  • 十六烷二酸和十四烷二酸浓度在GDC-0810存在时未升高。

关键数值与推荐

  • GCDCA-3G和GDCA-3G的Cmax升高与既往低剂量利福平合用及药物基因组学研究报道一致。

临床怎么用

  • 临床药学中可考虑将GCDCA-3G和GDCA-3G作为检测OATP1B弱抑制的补充生物标志物。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Endogenous biomarkers of drug transporters are promising tools to evaluate in vivo transporter function and potential alterations in the pharmacokinetics of their substrates. We have previously reported that coproporphyrin I/III captured the weak inhibition of OATP1B transporters by GDC-0810. In this study, we measured plasma concentrations of additional biomarkers, namely fatty acids, bile acids and their sulphate or glucuronide conjugates in the presence and absence of GDC-0810. Concentrations of hexadecanedioate and tetradecanedioate did not increase in the presence of GDC-0810. Among bile acids and their conjugates, glycochenodeoxycholate and glycodeoxycholate 3-O-glucuronides (GCDCA-3G and GDCA-3G) showed Cmax increases with geometric mean ratio (95% confidence interval) of 1.58 (1.13-2.22) and 1.49 (1.21-1.83), consistent with previous reports from low-dose rifampin co-administration and pharmacogenetic studies. These results suggest that GCDCA-3G and GDCA-3G are two more promising biomarkers that may capture weak OATP1B inhibition in addition to coproporphyrin I/III.

来源:Br J Clin Pharmacol,查看原文。版权归原作者所有。

引用

  1. Yoshida K, Jaochico A, Mao J, et al. Glycochenodeoxycholate and glycodeoxycholate 3-O-glucuronides, but not hexadecanedioate and tetradecanedioate, detected weak inhibition of OATP1B caused by GDC-0810 in humans. Br J Clin Pharmacol. 2023. PMID: 36735594. doi:10.1111/bcp.15679

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。